Hologic receives FDA 510(k) clearance to market SculpSure® for non-invasive body contouring

Hologic Receives FDA 510(k) Clearance to Market SculpSure® for Non-Invasive Body Contouring (Lipolysis) of the Submental Area (Under the Chin)
share Share

Patients in Clinical Studies Report 100% Satisfaction Rate


Hologic, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an expanded FDA 510(k) clearance for Cynosure's non-invasive body contouring product, SculpSure®. The state-of-the-art body contouring laser treatment is now cleared to treat a double chin (also known as the submental area), marking the product's sixth cleared body treatment area. SculpSure® is also cleared to treat the abdomen, love handles (flanks), back, and inner and outer thighs.


"Most patients in the 57-person clinical trial received two brief treatments six weeks apart," said Dr. Lawrence Bass, board certified plastic surgeon and a principal investigator in the SculpSure clinical trials. "The short treatment time, 100% satisfaction rate, and dramatic contour reductions typically seen in the study patients give SculpSure the edge as the treatment of choice for the submental area."  


SculpSure® is an advanced, non-invasive body contouring treatment that helps patients achieve a natural-looking, slimmer appearance. The fully customizable treatment uses a laser to raise the temperature of body fat to precisely disrupt and destroy fat cells under the skin. The fat cells are then naturally eliminated over time and do not return. Each treatment lasts approximately 25 minutes and requires no surgery or downtime.


"We are encouraged that our chin treatment was proven effective on patients with a body mass index (BMI) up to 43, while our competition in the non-invasive arena is only FDA-cleared to treat patients with a BMI up to 30," said Kevin Thornal, Divisional President of Cynosure at Hologic. "We are excited to provide our customers with a competitive advantage that can further widen their patient communities."


To learn more about SculpSure, please visit www.SculpSure.com.


Source & Image Credit: Hologic

Find More About Hologic

«« Brain disconnections may cause Parkinson’s hallucinations

3D imaging in hilar cholangiocarcinoma diagnosis »»

Published on : Sat, 30 Sep 2017

Related Articles
Hologic CEO Steve MacMillan to Ring Nasdaq Opening Bell on October 2 to Kick Off Breast Cancer Awareness Month

Trailblazing Company Behind the Genius™ 3D Mammography™ Exam Celebrates Year of Innovations in Breast Health Hologic,... Read more

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2017 on Wednesday, November 8, 2017

Hologic, Inc. has announced that the Company plans to release its financial results for the fourth quarter of fiscal 2017 on Wednesday,... Read more

Hologic announces offering of $350 Million of Senior Notes due 2025

- Proceeds Expected to Contribute to Retirement of Remaining Convertible Notes - Hologic, Inc. has announced... Read more

Hologic, SculpSure®,Non-Invasive Body Contouring ,Lipolysis,Kevin Thornal,Cynosure Hologic Receives FDA 510(k) Clearance to Market SculpSure® for Non-Invasive Body Contouring (Lipolysis) of the Submental Area (Under the Chin)

No comment

Please login to leave a comment...

Highlighted Products